Webinar: Capitalizing on CDMO Expertise in Aseptic Fill/Finish, Presented by Samsung Biologics

Discover the secret to rapid tech transfer and expedited batch release in aseptic fill/finish with real case studies from a global CDMO. And that’s not all — watch the audience Q&A to uncover the insights that your industry peers were most eager to gain.

From optimized tech transfer, to expedited batch release, to a team culture of expertise, David King, Director of Drug Product Operations at Samsung Biologics, will discuss pivotal moments in past projects and how Samsung Biologics leverages its CDMO expertise to meet accelerated timelines in aseptic fill/finish manufacturing.

In this webinar, you will learn:

  • How Samsung Biologics integrates their clients' operation philosophies with their aseptic fill/finish expertise, equipment design, and facility
  • How to build client/CDMO relationships based on trust and expertise
  • Preemptive approaches to ensure a rapid and seamless tech transfer for on-time delivery to patients
  • Personalized insights from the audience Q&A at the end of the presentation

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Samsung Biologics

Samsung Biologics is a full service CDMO focused on the development and manufacture of biologics for the improvement of global healthcare. Established in 2011, Samsung Biologics offers a full range of solutions for the biopharmaceutical industry, including cell line process and analytical method development, analytical services, and bulk cGMP manufacturing of drug substance and drug product from clinical to commercial scale. Based in Incheon, South Korea, Samsung Biologics’ four manufacturing facilities are optimized for the production of monoclonal and recombinant drug substance and drug product, and operate with strict adherence to quality assurance, quality control and global regulatory compliance standards. Samsung Biologics' Plant 4, the world's largest single biomanufacturing plant, began GMP operations in 2022.